Eli Lilly inks OpenAI deal for discovering new antibiotics

Eli Lilly is teaming up with OpenAI on a quest to develop new treatments that overcome antimicrobial resistance (AMR).

The Big Pharma will use the generative artificial intelligence from OpenAI to come up with new solutions for microbial infections. Financial details of the deal, which was announced June 25, were not disclosed.